Hematopoietic cell transplantation for non-Hodgkin's lymphoma: Yesterday, today, and tomorrow

Journal of Clinical Oncology

Volumn 26, Issue 18, 2008, Pages 2927-2929

  Appelbaum, Frederick R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CRYOPRESERVATION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIMODALITY CANCER THERAPY; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; NOTE; PRIORITY JOURNAL; RECURRENT CANCER; REDUCED INTENSITY CONDITIONING; TREATMENT INDICATION; WHOLE BODY RADIATION; ARTICLE;

COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 46449101522     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.7479     Document Type: Note

References (26)

1. Appelbaum FR, Thomas ED: Review of the use of marrow transplantation in the treatment of non-Hodgkin's lymphoma. J Clin Oncol 1:440-447, 1983
2. Appelbaum FR, Herzig GP, Ziegler JL, et al: Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 52:85-95, 1978
3. Appelbaum FR, Fefer A, Cheever MA, et al: Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. Blood 58:509-513, 1981
4. Appelbaum FR, Thomas ED, Buckner CD, et al: Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogeneic marrow transplantation. Hematol Oncol 1:149-157, 1983
5. Center for International Blood and Marrow Transplant Research: www.cibmtr.org.
6. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
7. Greb A, Bohlius J, Trelle S, et al: High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma: Results of a comprehensive meta-analysis. Cancer Treat Rev 33:338-346, 2007
8. Peniket AJ, Ruiz DEM, Taghipour G, et al: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678, 2003
9. Baron F, Storb R, Storer BE, et al: Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopietic cell transplantation. J Clin Oncol 24:4150-4157, 2006
10. Brice P, Simon D, Bouabdallah R, et al: High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 11:1585-1590, 2000
11. Schouten HC, Qian W, Kvaloy S, et al: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 21:3918-3927, 2003
12. Rohatiner AZ, Nadler L, Davies AJ, et al: Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up. J Clin Oncol 25:2554-2559, 2007
13. Lenz G, Dreyling M, Schiegnitz E, et al: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104: 2667-2674, 2004
14. Deconinck E, Foussard C, Milpied N, et al: High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS. Blood 105:3817-3823, 2005
15. Sebban C, Mounier N, Brousse N, et al: Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 108:2540-2544, 2006
16. Rezvani AR, Sandmaier BM, Storer B, et al: Outcomes of allogeneic hematopoietic stem cell transplantation (HCT) after non-myeloablative conditioning in relapsed, refractory, or transformed indolent non-Hodgkin lymphoma (NHL). Blood 108:891a, 2006 (abstr 3124)
17. Khouri I, Saliba R, Hosing C, et al: Autologous stem cell vs nonmyeloablative allogeneic transplantation after high-dose rituximab-containing conditioning regimens for relapsed chemosensitive follicular lymphoma. Blood 106:19a, 2005 (abstr 48)
18. Gopal AK, Rajendran JG, Petersdorf SH, et al: High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002
19. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
20. Maris MB, Sandmaier BM, Storer BE, et al: Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535-3542, 2004
21. Corradini P, Dodero A, Zallio F, et al: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004
22. Press OW, Eary JF, Gooley T, et al: A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas (Plenary paper). Blood 96: 2934-2942, 2000
23. Gopal AK, Gooley TA, Maloney DG, et al: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis. Blood 102:2351-2357, 2003
24. Gottschalk S, Heslop HE, Rooney CM: Adoptive immunotherapy for EBV-associated malignancies (review). Leuk Lymphoma 46:1-10, 2005
25. + cytotoxic T lymphocytes. Molecular Therapy 9:577-586, 2004
26. Wang J, Jensen M, Lin Y, et al: Optimizing adoptive polyclonal t cell immunotherapy of lymphomas, using a chimeric t cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 18:712-725, 2007